Gainers

• Estrella Immunopharma (NASDAQ:ESLA) shares moved upwards by 34.4% to $1.4 during Thursday's regular session. The market value of their outstanding shares is at $39.2 million.
• Liminatus Pharma (NASDAQ:LIMN) shares increased by 21.67% to $1.74. The company's market cap stands at $38.7 million.
• TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 20.39% to $10.33. The market value of their outstanding shares is at $7.8 million.
• Phibro Animal Health (NASDAQ:PAHC) stock rose 19.46% to $48.98. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q2 earnings report came out yesterday.
• AIM ImmunoTech (AMEX:AIM) stock increased by 19.43% to $1.26. The company's market cap stands at $3.4 million.
• CytoMed Therapeutics (NASDAQ:GDTC) stock increased by 18.83% to $1.01. The market value of their outstanding shares is at $9.9 million.

Losers

• CollPlant Biotechnologies (NASDAQ:CLGN) stock decreased by 41.0% to $0.95 during Thursday's regular session. The company's market cap stands at $20.5 million.
• Akanda (NASDAQ:AKAN) stock decreased by 22.23% to $0.91. The market value of their outstanding shares is at $2.4 million.
• Accuray (NASDAQ:ARAY) shares fell 21.43% to $0.59. The company's market cap stands at $85.7 million. The company's, Q2 earnings came out yesterday.
• Ernexa Therapeutics (NASDAQ:ERNA) stock fell 20.81% to $0.67. The company's market cap stands at $6.6 million.
• Ensysce Biosciences (NASDAQ:ENSC) stock decreased by 20.46% to $0.45. The market value of their outstanding shares is at $2.0 million.
• Aspire Biopharma Hldgs (NASDAQ:ASBP) stock decreased by 16.13% to $1.3. The company's market cap stands at $6.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.